L Daniel Browne has sold RVNC and made no open-market buys since Oct 2016

CEO and President at Revance Therapeutics, Inc.

SEC CIK 0001597583 · Filings on SEC.gov ↗

$0Bought

$4.2MSold

NoneLast buy

Every filing

14 filings since Oct 2016, newest first

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$180K−7.0%Mar 19

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$96K−3.0%Feb 20

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$204K−4.0%Mar 16

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$858K−17.0%Mar 9

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$190K−5.0%Nov 24

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$200K−5.0%Oct 20

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$179K−5.0%Sep 22

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$519K−13.0%Aug 25

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$649K−16.0%May 24

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$227K−5.0%Feb 24

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$237K−6.0%Jan 27

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$251K−6.0%Dec 30

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$215K−5.0%Nov 25

RVNCSell

Revance Therapeutics, Inc.

CEO and President

$178K−5.0%Oct 28

Filings come from SEC EDGAR. Not investment advice.